News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023
byAudrey Abella
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
27 Sep 2023

Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
26 Sep 2023
byAudrey Abella
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.
26 Sep 2023






